Cereno Scientific launches season 2 of the Insights Video Series

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced the launch of season 2 of the Insights Video Series recorded at the ESC Congress in August 2023. The video series will provide insights into the company’s drug development portfolio focused on treatments for pulmonary arterial hypertension (PAH) and thrombosis prevention, through interviews and conversations with global thought leaders.

The Insights Series is conducted as a series of interviews and conversations with internationally renowned scientific experts, who share their knowledge and insights to provide a greater understanding of the company's intensified focus on further developing the product portfolio. 

“The season 2 of the Insights series promises to offer valuable insights into our drug candidates and the great unmet medical need in our target indications – PAH and thrombosis prevention. We have had some significant advancements in our development programs recently, especially with CS1 in PAH; showing remarkable data in a patient case study and in Q4, we are expecting read-out from the data quality control initiative in the Phase II study. This, combined with the promising data from our two preclinical drug candidates in thrombosis, ensures a season of informative and exciting video content. We are delighted to share the expertise of global thought leaders to provide insight into the inner workings of drug development at Cereno,” said Sten R. Sörensen, CEO at Cereno Scientific.

Global thought leaders include Raymond L. Benza, System Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City, Principal Investigator of the Phase II study of CS1, and member of Cereno’s Scientific Advisory Board; Phil B. Adamson, Divisional Vice President and Chief Medical Officer Heart Failure Division, Abbott, and collaborative partner in the Phase II study of CS1; and Michael Holinstat, Prof. at University of Michigan Medical School; and Director of Translational Research, Cereno Scientific.

The video series will be available on Cereno’s website, LinkedIn and YouTube.

For further information, please contact:

Eva Jagenheim, CFO
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.